Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dna X (SONM) Gross Margin (2018 - 2025)

Historic Gross Margin for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to 11.2%.

  • Dna X's Gross Margin fell 169700.0% to 11.2% in Q3 2025 from the same period last year, while for Sep 2025 it was 18.33%, marking a year-over-year decrease of 85000.0%. This contributed to the annual value of 17.02% for FY2024, which is 36200.0% down from last year.
  • Per Dna X's latest filing, its Gross Margin stood at 11.2% for Q3 2025, which was down 169700.0% from 7.55% recorded in Q2 2025.
  • In the past 5 years, Dna X's Gross Margin ranged from a high of 49.97% in Q1 2025 and a low of 3.06% during Q4 2021
  • Moreover, its 5-year median value for Gross Margin was 16.49% (2023), whereas its average is 18.39%.
  • As far as peak fluctuations go, Dna X's Gross Margin tumbled by -393400bps in 2024, and later soared by 326700bps in 2025.
  • Over the past 5 years, Dna X's Gross Margin (Quarter) stood at 3.06% in 2021, then soared by 633bps to 16.3% in 2022, then skyrocketed by 134bps to 38.12% in 2023, then plummeted by -103bps to 1.22% in 2024, then surged by 1017bps to 11.2% in 2025.
  • Its Gross Margin was 11.2% in Q3 2025, compared to 7.55% in Q2 2025 and 49.97% in Q1 2025.